ReviewJournal of medical imaging and radiation oncology2025
Differentiation Between Radiation Necrosis and True Tumour Progression After Radiotherapy to Intracranial Metastases.
Review in Journal of medical imaging and radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Magnetic resonance spectroscopy (MRS) for differentiating tumour recurrence from radiation necrosis in treated intra-axial brain tumours.The Cochrane database of systematic reviews · 2026Pooled it
- Post-therapy imaging of adult brain tumours: patterns, pitfalls, and practical framework.Insights into imaging · 2026Article
- Headache as a Sentinel Signal After Cranial Radiotherapy: A Symptom-Driven Approach to Pathophysiology and Management.Neurology international · 2026Review
- Imaging response assessment in metastatic renal cell carcinoma: a radiologist's guide to contemporary therapeutic strategies.Abdominal radiology (New York) · 2026Review
- First-in-human evidence of multidrug resistance reversal in solid tumors: a cohort analysis of carbon nanoparticles‑Fe(II) complex trials.BMC cancer · 2026Article
- Cesium-131 brachytherapy for central nervous system salvage therapy.Journal of neuro-oncology · 2026Article
- Advances in the prevention and treatment of radiation-induced brain necrosis: a narrative review.Frontiers in oncology · 2026Review
- Tislelizumab plus chemotherapy followed by anlotinib maintenance therapy in a patient with extensive-stage small cell lung cancer and intracranial recurrence after palliative whole-brain radiotherapy: a case report and literature review.Frontiers in immunology · 2026Review
- Is 18F-PSMA PET/CT a reliable imaging modality to evaluate the status of recurrent/residual brain tumors in post-treatment patients?Journal of neuro-oncology · 2025Article
- Long-term clinical outcomes of bevacizumab for treatment of stereotactic radiosurgery-induced radiation necrosis in patients with brain metastases.Journal of neuro-oncology · 2025Article
- A feasibility trial of delayed resection for brain metastases following pre-operative stereotactic radiosurgery.Journal of neuro-oncology · 2025Article
- Impact of stereotactic radiosurgery timing relative to immune checkpoint blockade administration on brain metastasis disease and radionecrosis outcomes.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Differentiating between radiation necrosis and true tumour progression after radiotherapy is challenging due to overlapping imaging appearances. This review outlines useful techniques and imaging features for making this distinction, as well as potential pitfalls. Both radiation necrosis and true tumour progression commonly manifest as peripherally enhancing lesions on post-contrast T1-weighted imaging, but the enhancing rim should be thin in radiation necrosis, while more discrete nodular enhancement suggests active tumour. Other features on post-contrast MRI that suggest radiation necrosis include enhancing lesions across anatomical boundaries, clustering of enhancing lesions and a change in lesion shape. Central diffusion restriction corresponding to the central necrotic area favours radiation necrosis, but there are potential pitfalls to be aware of, including hypercellular tumours, coagulative necrosis due to bevacizumab and intra-lesional haemorrhage. Radiation necrosis typically results in small, clustered foci of magnetic susceptibility on susceptibility-sensitive sequences, and the absence of such foci should raise concern for active tumour. When uncertainty remains, ancillary techniques such as MR perfusion and amino acid PET can improve confidence. Atypical appearances of radiation necrosis can occur, for example, cystic radiation necrosis or radiation necrosis occurring after radiotherapy to adjacent structures. It is also important for the radiologist to be aware of additional factors that may increase the likelihood of either radiation necrosis or tumour necrosis or influence patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.